Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome
Open accessThe DOI matches its Crossref record; 24 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—We explored whether cardiovascular disease (CVD) risk and the effects of fenofibrate differed in subjects with and without metabolic syndrome and according to various features of metabolic syndrome defined by the Adult Treatment Panel III (ATP III) in subjects with type 2 diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. RESEARCH DESIGN AND METHODS—The prevalence of metabolic syndrome and its features was calculated. Cox proportional models adjusted for age, sex, CVD status, and baseline A1C levels were used to determine the independent contributions of metabolic syndrome features to total CVD event rates and the effects of fenofibrate. RESULTS—More than 80% of FIELD participants met the ATP III criteria for metabolic syndrome. Each ATP III feature of metabolic syndrome, apart from increased waist circumference, increased the absolute risk of CVD events over 5 years by at least 3%. Those with marked dyslipidemia (elevated triglycerides ≥2.3 mmol/l and low HDL cholesterol) were at the highest risk of CVD (17.8% over 5 years). Fenofibrate significantly reduced CVD events in those with low HDL cholesterol or hypertension. The largest effect of fenofibrate to reduce CVD risk was observed in subjects with marked dyslipidemia in whom a 27% relative risk reduction (95% CI 9–42, P = 0.005; number needed to treat = 23) was observed. Subjects with no prior CVD had greater risk reductions than the entire group. CONCLUSIONS—Metabolic syndrome components identify higher CVD risk in individuals with type 2 diabetes, so the absolute benefits of fenofibrate are likely to be greater when metabolic syndrome features are present. The highest risk and greatest benefits of fenofibrate are seen among those with marked hypertriglyceridemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Potential use of fibrates to reduce TG levels is quite limited, due to the risk of myopathy if given with statins and the little benefit demonstrated in RCTs, aside from sub-group analysis including subjects with very high TG levels.200,270,271”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [270]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Specifically, the five year FIELD Study, which evaluated 9,795 subjects with type 2 diabetes who were 50–75 years of age, demonstrated a reduction of 24% of non-fatal myocardial infraction (MI) for those receiving FF-compared to placebo (p=0.01).”
From Fenofibrate and metabolic syndrome (2010) · cites this paper as [46]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, a post hoc analysis of data from the FIELD study suggested a benefit for patients with both elevated triglyceride levels and low HDL cholesterol levels.12”
From Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus (2010) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“Elevation of TGs or low HDL-C is seen in about half of subjects with T2DM. 351”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [351]
The cited source says what the claim attributes to it.
In the citing paper
“In a post hoc analysis of the FIELD study, fenofibrate reduced CVD events by 27% in those with elevated TGs [>2.3 mmol/L (~204 mg/dL)] and reduced HDL-C (NNT ¼ 23).351”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [351]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Hokanson, J. E., & Austin, M. A. (1996) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199604000-00014 · Cited by 1,706
Alexander, C. M., Landsman, P. B., Teutsch, S. M., & Haffner, S. M. (2003) · Diabetes · doi:10.2337/diabetes.52.5.1210 · Cited by 1,475 · cited 1×
“National Health and Nutrition Examination Survey III survey and also in individuals with newly diagnosed diabetes (11,12).”
BackgroundAtherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
Austin, M. A., King, M. C., Vranizan, K. M., & Krauss, R. M. (1990) · Circulation · doi:10.1161/01.cir.82.2.495 · Cited by 1,411 · cited 1×
“ies (8,14), presumably reflecting a tendency for high nonfasting triglyceride levels and higher numbers of remnant particles and may be associated with more extreme abnormalities in other biological processes (such as oxidative stress, inflammation, and hypercoagulability), leading to more aggressive atherosclerosis (…”
BackgroundSarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408 · cited 1×
“ies (8,14), presumably reflecting a tendency for high nonfasting triglyceride levels and higher numbers of remnant particles and may be associated with more extreme abnormalities in other biological processes (such as oxidative stress, inflammation, and hypercoagulability), leading to more aggressive atherosclerosis (…”
Background
Cited by
Items 101–200 of 549
Maki, K. C., Bays, H. E., & Dicklin, M. R. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.04.003 · Cited by 83
Triglycerides and cardiovascular disease
Esan, O., & Wierzbicki, A. S. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000862 · Cited by 81
Consensus statement on management of dyslipidemia in Indian subjects
Chandra, K. S., Bansal, M., Nair, T., Iyengar, S. S., Gupta, R., Manchanda, S. C., Mohanan, P. P., Rao, V. D., Manjunath, C. N., Sawhney, J. P. S., et al. (2014) · Indian Heart Journal · doi:10.1016/j.ihj.2014.12.001 · Cited by 102
The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid Trial
Ginsberg, H. N. (2011) · Diabetes Care · doi:10.2337/dc11-s203 · Cited by 82
Saroglitazar for the treatment of dyslipidemia in diabetic patients
Joshi, S. R. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1009894 · Cited by 79
Ferri, N., & Ruscica, M. (2016) · Endocrine · doi:10.1007/s12020-016-0939-0 · Cited by 89
Management of Diabetes in the Elderly
Bansal, N., Dhaliwal, R., & Weinstock, R. S. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.11.008 · Cited by 91
Crakes, K. R., Rocha, C. S., Grishina, I., Hirao, L. A., Napoli, E., Gaulke, C. A., Fenton, A. N., Datta, S., Arredondo, J., Marco, M. L., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908977116 · Cited by 81
Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments
Scorletti, E., Calder, P. C., & Byrne, C. D. (2011) · Endocrine · doi:10.1007/s12020-011-9530-x · Cited by 80
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Levelt, E., Gulsin, G. S., Neubauer, S., & McCann, G. P. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0724 · Cited by 84
Disentangling Genetic Risks for Metabolic Syndrome
van Walree, E. S., Jansen, I. E., Bell, N. Y., Savage, J. E., de Leeuw, C., Nieuwdorp, M., van der Sluis, S., & Posthuma, D. (2022) · Diabetes · doi:10.2337/db22-0478 · Cited by 71
Hendrani, A. D., Adesiyun, T., Quispe, R., Jones, S. R., Stone, N. J., Blumenthal, R. S., & Martin, S. S. (2016) · World Journal of Cardiology · doi:10.4330/wjc.v8.i2.201 · Cited by 85
van Wijk, J. P. H., & Cabezas, M. C. (2012) · International Journal of Vascular Medicine · doi:10.1155/2012/201027 · Cited by 68
Hypertriglyceridemia - Common Causes, Prevention and treatment Strategies
Rygiel, K. (2018) · Current Cardiology Reviews · doi:10.2174/1573403x14666180123165542 · Cited by 67
The Cardiovascular Effects of Peroxisome Proliferator-activated Receptor Agonists
Friedland, S. N., Leong, A., Filion, K. B., Genest, J. J., Lega, I. C., Mottillo, S., Poirier, P., Reoch, J., & Eisenberg, M. J. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.08.025 · Cited by 73
Should low high-density lipoprotein cholesterol (HDL-C) be treated?
Toth, P. P., Barylski, M., Nikolić, D., Rizzo, M., Montalto, G., & Banach, M. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.11.002 · Cited by 73
Cheang, W. S., Tian, X. Y., Wong, W. T., & Huang, Y. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13029 · Cited by 64
Guía de la ESC/EAS sobre el manejo de las dislipemias
Reiner, Ž., Catapano, A. L., Backer, G. D., Graham, I. M., Taskinen, M., Wiklund, O., Agewall, S., Alegría, E., Chapman, M. J., Durrington, P. N., et al. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.09.014 · Cited by 80
Self-citationIto, M. K. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.012 · Cited by 76
Eeg‐Olofsson, K., Guðbjörnsdóttir, S., Eliasson, B., Zethelius, B., & Cederholm, J. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.07.010 · Cited by 71
Sosale, A., Saboo, B., & Sosale, B. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s49592 · Cited by 71
Postprandial Plasma Phospholipids in Men Are Influenced by the Source of Dietary Fat
Meikle, P. J., Barlow, C. K., Mellett, N. A., Mundra, P. A., Bonham, M. P., Larsen, A., Cameron‐Smith, D., Sinclair, A. J., Nestel, P. J., & Wong, G. (2015) · Journal of Nutrition · doi:10.3945/jn.115.210104 · Cited by 68
PCSK9 and diabetes: is there a link?
Momtazi‐Borojeni, A. A., Banach, M., Pirro, M., Stein, E. A., & Sahebkar, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.006 · Cited by 65
Sottero, B., Gargiulo, S., Russo, I., Barale, C., Poli, G., & Cavalot, F. L. (2015) · Medicinal Research Reviews · doi:10.1002/med.21349 · Cited by 83
Davidson, M. H., Rosenson, R. S., Maki, K. C., Nicholls, S. J., Ballantyne, C. M., Mazzone, T., Carlson, D. M., Williams, L. A., Kelly, M. T., Camp, H. S., et al. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.302926 · Cited by 64
Maki, K. C., Guyton, J. R., Orringer, C. E., Hamilton-Craig, I., Alexander, D. D., & Davidson, M. H. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.03.008 · Cited by 62
Kolovou, G. D., Watts, G. F., Mikhailidis, D. P., Pérez-Martínez, P., Mora, S., Bilianou, H., Panotopoulos, G., Katsiki, N., Ooi, T. C., Lopez-Miranda, J., et al. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190507110519 · Cited by 61
"The metabolic syndrome... is dead": These reports are an exaggeration
Tenenbaum, A., & Fisman, E. Z. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-11 · Cited by 67
Wadham, C., & Mangoni, A. A. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902785172 · Cited by 63
Alexopoulos, A., Qamar, A., Hutchins, K., Crowley, M. J., Batch, B. C., & Guyton, J. R. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1136-3 · Cited by 75
Milionis, H., Moutzouri, Kei, & Elisaf (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s5593 · Cited by 59
Mapping body fat distribution: A key step towards the identification of the vulnerable patient?
Arsenault, B. J., Beaumont, E. P., Després, J.-P., & Larose, E. (2012) · Annals of Medicine · doi:10.3109/07853890.2011.605387 · Cited by 58
HIGH PREVALENCE OF SLEEP DISORDERED BREATHING IN PATIENTS WITH DIABETIC MACULAR EDEMA
Mason, R. H., West, S. D., Kiire, C. A., Groves, D. C., Lipinski, H. J., Jaycock, A., Chong, V. N., & Stradling, J. R. (2012) · Retina · doi:10.1097/iae.0b013e318259568b · Cited by 61
Triglycerides and ASCVD risk reduction: recent insights and future directions
Hussain, A., Ballantyne, C. M., Saeed, A., & Virani, S. S. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00846-8 · Cited by 57
Soran, H., Schofield, J. D., Adam, S., & Durrington, P. N. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000318 · Cited by 49
Role of HDL in Those with Diabetes
Santos‐Gallego, C. G., & Rosenson, R. S. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0512-5 · Cited by 65
Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective
Elam, M., Lovato, L. C., & Ginsberg, H. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328341a5a8 · Cited by 56
Combination therapy of statins and fibrates in the management of cardiovascular risk
Fiévet, C., & Staels, B. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328332e9ef · Cited by 60
Hejazi, N., Rajikan, R., Choong, C. L. K., & Shahar, S. (2013) · BMC Public Health · doi:10.1186/1471-2458-13-758 · Cited by 55
Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes
Khavandi, M., Duarte, F., Ginsberg, H. N., & Reyes‐Soffer, G. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0818-1 · Cited by 66
Future perspectives of the pharmacological management of diabetic dyslipidemia
Patti, A. M., Giglio, R. V., Παπάνας, Ν., Rizzo, M., & Rizvi, A. A. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1567328 · Cited by 58
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Toth, P. P. (2010) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(10)79553-6 · Cited by 55
Impact of lifestyle modification on glycemic control in patients with type 2 diabetes mellitus
Sanghani, N. B., Parchwani, D. N., Palandurkar, K. M., Shah, A. M., & Dhanani, J. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.122618 · Cited by 72
The Role of High-Density Lipoprotein Cholesterol in 2022
Sirtori, C. R., Corsini, A., & Ruscica, M. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01012-y · Cited by 60
Use of fibrates in the metabolic syndrome: A review
Shipman, K. E., Strange, R. C., & Ramachandran, S. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i5.74 · Cited by 51
Omega-3 Fatty Acids in Cardiovascular Disease and Diabetes: a Review of Recent Evidence
Bhat, S. Z., Sarkar, S., Zaffar, D., Dandona, P., & Kalyani, R. R. (2023) · Current Cardiology Reports · doi:10.1007/s11886-022-01831-0 · Cited by 57
Preventing diabetic complications: A primary care perspective
Zimmet, P. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.01.016 · Cited by 64
on behalf of the FIELD Study Investigators, d’Emden, M. C., Jenkins, A. J., Li, L., Zannino, D., Mann, K. P., Best, J. D., Stuckey, B. G. A., Park, K., Saltevo, J., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3344-3 · Cited by 49
Self-citationRutter, M. K., & Nesto, R. W. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr154 · Cited by 58
Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes
Triolo, M., Annema, W., de Boer, J. F., Tietge, U. J. F., & Dullaart, R. P. F. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12226 · Cited by 49
Ginsberg, H. N., Hounslow, N. J., Senko, Y., Suganami, H., Bogdanski, P., Ceska, R., Kalina, A., Libis, R. A., Supryadkina, T. V., & Hovingh, G. K. (2022) · Diabetes Care · doi:10.2337/dc21-1288 · Cited by 48
Kranenburg, G., van der Graaf, Y., van der Leeuw, J., Nathoe, H. M. W., de Borst, G. J., Kappelle, L. J., Visseren, F. L. J., & Westerink, J. (2015) · Diabetes Care · doi:10.2337/dc15-0493 · Cited by 48
Hermans, M. P., & Valensi, P. E. (2018) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000398 · Cited by 57
JCS 2023 Guideline on the Primary Prevention of Coronary Artery Disease
Fujiyoshi, A., Kohsaka, S., Hata, J., Hara, M., Kai, H., Masuda, D., Miyamatsu, N., Nishio, Y., Ogura, M., Sata, M., et al. (2024) · Circulation Journal · doi:10.1253/circj.cj-23-0285 · Cited by 60
Managing Diabetes and Cardiovascular Risk in Chronic Kidney Disease Patients
Lovre, D., Shah, S., Sihota, A., & Fonseca, V. A. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.006 · Cited by 46
Karalis, D. G. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0462-y · Cited by 59
Early investigational drugs targeting PPAR-α for the treatment of metabolic disease
Liu, Z.-M., Hu, M., Chan, P., & Tomlinson, B. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1006359 · Cited by 45
Dysfunctional HDL as a Therapeutic Target for Atherosclerosis Prevention
Ossoli, A., Pavanello, C., Giorgio, E., Calabresi, L., & Gomaraschi, M. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180316115726 · Cited by 49
Noguchi, T., Kobayashi, J., Yagi, K., Nohara, A., Yamaaki, N., Sugihara, M., Ito, N., Oka, R., Kawashiri, M., Tada, H., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.02.012 · Cited by 49
López-Jiménez, F. A., Simha, V., Thomas, R. J., Allison, T. G., Basu, A., Fernandes, R., Hurst, R. T., Kopecky, S. L., Kullo, I. J., Mulvagh, S. L., et al. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.06.016 · Cited by 49
Pharmacotherapies for lipid modification: beyond the statins
Gotto, A. M., & Moon, J. E. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.117 · Cited by 46
Management of dyslipidemia in people with type 2 diabetes mellitus
Dunn, F. L. (2010) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-010-9132-6 · Cited by 46
Fruchart, J. C., Sacks, F. M., Hermans, M. P., & on behalf of the International Steering Committee of Ri (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.489341 · Cited by 44
Management of Hypertriglyceridemia in the Diabetic Patient
Jialal, I., Amess, W., & Kaur, M. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0124-4 · Cited by 46
Recent Clinical Studies of the Effects of Lipid-Modifying Therapies
Gotto, A. M., & Moon, J. E. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.04.003 · Cited by 49
Penno, G., Solini, A., Zoppini, G., Fondelli, C., Trevisan, R., Vedovato, M., Gruden, G., Lamacchia, O., Pontiroli, A. E., Arosio, M., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125512 · Cited by 43
Hamilton, S. J., Chew, G. T., Davis, T. M. E., & Watts, G. F. (2010) · Clinical Science · doi:10.1042/cs20090568 · Cited by 42
Cardiovascular disease prevention strategies for type 2 diabetes mellitus
Katsiki, N., Purrello, F., Tsioufis, C., & Mikhailidis, D. P. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1351946 · Cited by 42
Irvin, M. R., Kabagambe, E. K., Tiwari, H. K., Parnell, L. D., Straka, R. J., Tsai, M., Ordovas, J. M., & Arnett, D. K. (2010) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.110.950667 · Cited by 41
for the BIP Study Group, Arbel, Y., Klempfner, R., Erez, A., Goldenberg, I., Benzekry, S., Shlomo, N., Fisman, E. Z., & Tenenbaum, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0332-6 · Cited by 40
Fenofibrate and metabolic syndrome
T. Kraja, A., A. Province, M., J. Straka, R., M. Ordovas, J., B. Borecki, I., & K. Arnett, D. (2010) · Endocrine, Metabolic & Immune Disorders - Drug Targets · doi:10.2174/187153010791213047 · Cited by 40
Brautbar, A., Covarrubias, D., Belmont, J. W., Lara, F., Virani, S. S., Jones, P. H., Leal, S. M., & Ballantyne, C. M. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.08.015 · Cited by 47
Jones, P. H., Cusi, K. J., Davidson, M. H., Kelly, M. T., Setze, C. M., Thakker, K. M., Sleep, D. J., & Stolzenbach, J. C. (2010) · American Journal of Cardiovascular Drugs · doi:10.2165/10061630-000000000-00000 · Cited by 47
Ting, R. Z. W., Yang, X., Yu, L. W., Luk, A. O. Y., Kong, A. P. S., Tong, P. C. Y., So, W., Chan, J. C. N., & Ronald, C. W. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-77 · Cited by 37
Fibrates: no ACCORD on their use in the treatment of dyslipidaemia
Wierzbicki, A. S. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833c1e74 · Cited by 41
Halcox, J., & Misra, A. (2014) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2014.0049 · Cited by 45
Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia
Nurmohamed, N. S., Dallinga‐Thie, G. M., & Stroes, E. S. G. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1768848 · Cited by 43
Medical strategies to reduce amputation in patients with Type 2 diabetes
Malik, R. A., Tesfaye, S. H., & Ziegler, D. (2013) · Diabetic Medicine · doi:10.1111/dme.12169 · Cited by 45
Yang, H., Gao, J., Ren, L., Li, S., Chen, Z., Huang, J., Zhu, S., & Pan, Z. (2017) · Journal of Diabetes Research · doi:10.1155/2017/3901392 · Cited by 39
Lipids, lipid-lowering therapy and diabetes complications
Valensi, P. E., & Picard, S. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.10.001 · Cited by 38
Role for Combination Therapy in Diabetic Dyslipidemia
Warraich, H. J., Wong, N. D., & Rana, J. S. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0589-5 · Cited by 41
Ezetimibe plus a Statin after Acute Coronary Syndromes.
Cannon, C. P., Blazing, M. A., & Braunwald, E. (2015) · PubMed · doi:10.1056/nejmc1509363 · Cited by 26
Agouridis, A. P., Rizos, C. V., Elisaf, M., & Filippatos, T. D. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.171 · Cited by 37
Mendelian Randomization and Estimation of Treatment Efficacy for Chronic Diseases
Schooling, C. M., Freeman, G., & Cowling, B. J. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws344 · Cited by 36
Bjornstad, P., Maahs, D. M., Wadwa, R. P., Pyle, L. L., Rewers, M., Eckel, R. H., & Snell‐Bergeon, J. K. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.08.008 · Cited by 38
Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?
Barter, P. J., & Rye, K. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.07.021 · Cited by 35
Recent advances in synthetic pharmacotherapies for dyslipidaemias
Sirtori, C. R., Yamashita, S., Greco, M. F., Corsini, A., Watts, G. F., & Ruscica, M. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319845314 · Cited by 34
Cardiovascular risk reduction with icosapent ethyl
Patel, P. N., Patel, S. M., & Bhatt, D. L. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000678 · Cited by 33
“16), though a post-hoc analysis of data did suggest that patients with both elevated triglyceride levels and low HDL-C levels were at the highest baseline risk and received the greatest potential clinical benefit from the treatment [17,18].”
BackgroundColhoun, H. M., Leiter, L. A., Müller-Wieland, D., Cariou, B., Ray, K. K., Tinahones, F. J., Domenger, C., Letierce, A., Israel, M., Samuel, R., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-0991-1 · Cited by 33
Dyslipidemia: Management Using Optimal Lipid-Lowering Therapy
Ito, M. K. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r127 · Cited by 39
Ogita, M., Miyauchi, K., Miyazaki, T., Naito, R., Konishi, H., Tsuboi, S., Dohi, T., Kasai, T., Yokoyama, T., Okazaki, S., et al. (2013) · Heart and Vessels · doi:10.1007/s00380-013-0330-5 · Cited by 36
Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo
Watts, G. F., Ooi, E. M. M., & Chan, D. C. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.04.005 · Cited by 35
Hermans, M. P. (2011) · Diabetes and Vascular Disease Research · doi:10.1177/1479164111407783 · Cited by 33
Tenenbaum, A., & Fisman, E. Z. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-24 · Cited by 36
Ibarra-Lara, L., Sánchez-Aguilar, M., Sánchez-Mendoza, A., del Valle‐Mondragón, L., Soria‐Castro, E., Carreón‐Torres, E., Díaz‐Díaz, E., Vázquez‐Meza, H., Guarner‐Lans, V., & Rubio-Ruiz, M. E. (2016) · Molecules · doi:10.3390/molecules22010031 · Cited by 34
Tarantino, N. M., Santoro, F., Gennaro, L. D., Correale, M., Guastafierro, F., Gaglione, A., Biase, M. D., & Brunetti, N. D. (2017) · Vascular Health and Risk Management · doi:10.2147/vhrm.s95044 · Cited by 40
A Very High Prevalence of Low HDL Cholesterol in Spanish Patients With Acute Coronary Syndromes
Pintó, X., Millán, J., Muñoz, A., Corbella, E., Hernández‐Mijares, A., Zuñiga, M., Mangas, A., & Pedro‐Botet, J. (2010) · Clinical Cardiology · doi:10.1002/clc.20774 · Cited by 36
Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects
Mijares, A. H., Ascaso, J. F., Blasco, M., Brea, Á., Díaz, Á., Mantilla, T., Pedro‐Botet, J., Pintó, X., & Millán, J. (2019) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.02.002 · Cited by 37
Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia
Wierzbicki, A. S. (2009) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32832c0b3d · Cited by 32
Metadata
- Authors
- Scott, R., O'Brien, R., Fulcher, G., Pardy, C., d'Emden, M., Tse, D., Taskinen, M.-R., Ehnholm, C., Keech, A., & on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators
- Affiliations
- Christchurch Hospital (NZ)
- Department of Medicine, Austin Hospital, University of Melbourne, Melbourne, Australia
- The University of Sydney (AU)
- Endocrine Research Unit, Royal Brisbane Hospital, Brisbane, Australia
- Helsinki University Hospital (FI)
- Department of Molecular Medicine, National Public Health Institute, Biomedicum, Helsinki, Finland
- Corresponding author
- Scott, Russell
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-03-01
- Volume
- 32
- Issue
- 3
- Pages
- 493-498
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2646035
- OpenAlex
- W1975018096
- Cited by
- 551
- References
- 26
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 15 · 2023: 20 · 2022: 12 · 2021: 23 · 2020: 32 · 2019: 34 · 2018: 28 · 2017: 31 · 2016: 32 · 2015: 43 · 2014: 41 · 2013: 41 · 2012: 38
- FWCI
- 33.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- Funders
- Medical Research Council
- National Health and Medical Research Council
- National Medical Research Council
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- fenofibrate, type 2 diabetes, metabolic syndrome, cardiovascular risk, hypertriglyceridemia, dyslipidemia, low HDL cholesterol, hypertension, field trials, NCEP ATP III criteria
- MeSH terms
- Hypolipidemic Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Humans, Male, Fenofibrate, Metabolic Syndrome, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.